Better Health for All

Onconetix's core business is focused on the research, development, and commercialization of innovative solutions for men's health and oncology, including the prostate cancer diagnostic test Proclarix and the BPH treatment ENTADFI.

The company is also developing vaccines for various infectious diseases, such as universal flu, norovirus/rotavirus, malaria, Streptococcus pneumoniae, and Chlamydia. All of its products and pipeline candidates are aimed at providing substantial health benefits, indicating 100% of its portfolio is health-positive. Proclarix has demonstrated a 5% or less probability of clinically significant cancer with a negative test in a subpopulation of patients with enlarged prostates, and a 96% sensitivity in an extended population, reducing unnecessary biopsies by 22%. ENTADFI has a favorable safety profile with fewer adverse sexual side effects compared to finasteride monotherapy. The company's former division, Veru, conducted a Phase 3 COVID-19 clinical trial, showing a 51.6% relative reduction in deaths with sabizabulin. However, the company's forward-looking statements consistently refer to risk factors detailed in SEC filings, without providing specific, comprehensive public data on risks and benefits for its products. While ENTADFI is available at pharmacies, there is no specific pricing data or information on access programs. The company's website offers information about BPH and ENTADFI prescribing, but no broader health education initiatives are detailed. Clinical trials for ENTADFI and sabizabulin were double-blinded and randomized, and Proclarix studies involved large cohorts, indicating strong ethical conduct.

Fair Pay & Worker Respect

No specific, concrete data points for Onconetix, Inc. (ONCO.US) related to any of the Fair Pay & Worker Respect KPIs were found in the provided articles. The articles either discuss other companies (Foremost Farms, Labcorp)

or provide general industry news or a company description without performance metrics for ONCO.US.

Honest & Fair Business

Onconetix, Inc. has a Business Code of Conduct and Ethics that includes a whistle-blower policy, allowing for anonymous reporting, maintaining confidentiality (subject to law), and prohibiting retaliation.

The company also emphasizes compliance with anti-corruption laws, specifically the Foreign Corrupt Practices Act (FCPA) and US export control laws, and requires waivers for certain activities. However, the company has faced regulatory compliance issues, including multiple delisting notices from Nasdaq for failing to file its Q1 2025 10-Q report and 2024 annual 10-K report, and for its stock price falling below the minimum bid price requirement.

Kind to Animals

Onconetix, Inc. has 0% of its products certified cruelty-free.

The company also reports 0% of its animal-related operations holding humane certifications. Onconetix conducts pre-clinical animal studies, indicating a policy that allows for animal testing without specific details on restrictions or reduction commitments.

Planet-Friendly Business

Sustainability data for Onconetix, Inc. is currently unavailable.

No quantitative data, regulatory actions, certifications, or comparisons related to environmental performance can be extracted from the provided articles. The cybersecurity report also does not include information on environmental matters.

Respect for Cultures & Communities

No specific, concrete evidence was found in the provided articles to assess Onconetix, Inc. against any of the Key Performance Indicators for the ethical value of Respect for Cultures & Communities. The available information focuses on financial data and employee counts

, and a general overview of Free, Prior, and Informed Consent (FPIC) , none of which provide company-specific actions or metrics related to community engagement or cultural respect.